Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-67571244 |
| Synonyms | |
| Therapy Description |
JNJ-67571244 is a bispecific antibody that binds to CD33 and CD3, which potentially activates T-lymphocytes leading to increased cytotoxicity and reduced tumor growth of CD33-expressing cancer cells (PMID: 32150609). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-67571244 | JNJ67571244|JNJ 67571244 | CD3 Antibody 119 CD33 Antibody 17 | JNJ-67571244 is a bispecific antibody that binds to CD33 and CD3, which potentially activates T-lymphocytes leading to increased cytotoxicity and reduced tumor growth of CD33-expressing cancer cells (PMID: 32150609). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03915379 | Phase I | JNJ-67571244 | A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Completed | USA | ESP | DEU | 0 |